Thioredoxin and thioredoxin reductase expression in thyroid cancer depends on tumour aggressiveness.

Thyroid cancer is the second most common malignancy following breast cancer in Arab females. Thioredoxin (TRX) is a small multi-functional redox protein with both intracellular and extracellular functions. The protein exists in either a reduced form (thioredoxin-SH2) or an oxidized form (thioredoxin-S2). TRX acts as an enhancement for growth factors and stimulates the growth of cancer cells. In this study of thyroid neoplasms, involving 121 female and 62 male patients, expression of TRX and TRX-R was studied using purified mouse anti-human TRX monoclonal antibody and anti-human TRX-R antiserum from rabbits, respectively. In order to delineate tumour cell growth, proliferating cell nuclear antigen (PCNA) polyclonal antibody was used. Compared to normal thyroid tissue, expression of TRX and TRX-R was increased in the cytoplasm and nuclei of thyroid cancer cells. Furthermore, TRX expression correlated with that of TRX-R. Of the 183 thyroid neoplasms investigated, overexpression of TRX-R was found in different types of neoplasms. The majority of carcinomas showed a correlation between strongly positive TRX and TRX-R expression and neoplastic cellular proliferation, as measured by PCNA. This indicates that increased TRX and TRX-R expression may be associated with tumourigenesis by acting as an autocrine growth stimulus. This study suggests that TRX immunoreactivity in thyroid tumours is a function of malignancy and cancer progression. In addition, secreted TRX can also act as an extracellular growth factor for both normal and tumour cells and enhance the sensitivity of the cells. Furthermore, this study emphasizes the potential benefits of anti-TRX/TRX-R agents in cancer therapeutics in the treatment of thyroid cancer.

[1]  F. Sinowatz,et al.  Role Of Prostate Stem Cells In Development And Cancer , 2008 .

[2]  P. Singal,et al.  Growth hormone in vascular pathology: neovascularization and expression of receptors is associated with cellular proliferation. , 2007, Anticancer research.

[3]  H. Namba,et al.  Overexpression of wild-type THRbeta1 suppresses the growth and invasiveness of human papillary thyroid cancer cells. , 2007, Anticancer research.

[4]  P. Davis,et al.  Hypothyroidism in the patient with cancer: how much thyroid supplementation is "safe"? , 2007, Archives of Otolaryngology - Head and Neck Surgery.

[5]  K. Ogawa,et al.  Hypothyroidism after radiotherapy for patients with head and neck cancer. , 2007, American journal of otolaryngology.

[6]  Caroline Kim,et al.  AKT activation promotes metastasis in a mouse model of follicular thyroid carcinoma. , 2005, Endocrinology.

[7]  P. Singal,et al.  The thioredoxin-thioredoxin reductase system adapts to human cancer growth by overexpression , 2005 .

[8]  A. Miyauchi,et al.  Decreased expression of cyclin G2 is significantly linked to the malignant transformation of papillary carcinoma of the thyroid. , 2003, Anticancer research.

[9]  K. Tonissen,et al.  The thioredoxin-thioredoxin reductase system: over-expression in human cancer. , 2003, Anticancer research.

[10]  B. Tatic.  Histopathological and immunohistochemical features of thyroid carcinoma , 2003 .

[11]  G. Powis,et al.  Properties and biological activities of thioredoxins. , 2001, Annual review of biophysics and biomolecular structure.

[12]  C. Reiners,et al.  Inverse association between age at the time of radiation exposure and extent of disease in cases of radiation‐induced childhood thyroid carcinoma in Belarus , 2000, Cancer.

[13]  N. Ordóñez,et al.  Thyroid transcription factor-1 is a marker of lung and thyroid carcinomas. , 2000, Advances in anatomic pathology.

[14]  Y. Yamaoka,et al.  Expression of thioredoxin and glutaredoxin, redox-regulating proteins, in pancreatic cancer. , 2000, Cancer detection and prevention.

[15]  R. Hondal,et al.  Thioredoxin reductase. , 2000, The Biochemical journal.

[16]  P. Ghezzi,et al.  Thioredoxin, a Redox Enzyme Released in Infection and Inflammation, Is a Unique Chemoattractant for Neutrophils, Monocytes, and T Cells , 1999, The Journal of experimental medicine.

[17]  Kohei Miyazono,et al.  Mammalian thioredoxin is a direct inhibitor of apoptosis signal‐regulating kinase (ASK) 1 , 1998, The EMBO journal.

[18]  F. Bakiri,et al.  The relative roles of endemic goiter and socioeconomic development status in the prognosis of thyroid carcinoma , 1998, Cancer.

[19]  L. Obeid,et al.  Thioredoxin Peroxidase Is a Novel Inhibitor of Apoptosis with a Mechanism Distinct from That of Bcl-2* , 1997, The Journal of Biological Chemistry.

[20]  D. Kirkpatrick,et al.  Selenium and the thioredoxin redox system: effects on cell growth and death. , 1997, Oncology research.

[21]  H. Nakamura,et al.  Redox regulation of cellular activation. , 1997, Annual review of immunology.

[22]  G. Powis,et al.  Cell growth stimulation by the redox protein thioredoxin occurs by a novel helper mechanism. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[23]  R. Hoermann,et al.  Thyroid stimulation by placental factors , 1993, Journal of endocrinological investigation.

[24]  G. Burrow.  Thyroid function and hyperfunction during gestation. , 1993, Endocrine reviews.

[25]  J. Yodoi,et al.  Thiordoxin regulates the DNA binding activity of NF-χB by reduction of a disulphid bond involving cysteine 62 , 1992 .

[26]  J. Yodoi,et al.  Thioredoxin regulates the DNA binding activity of NF-kappa B by reduction of a disulphide bond involving cysteine 62. , 1992, Nucleic acids research.